NEW YORK – Pfizer has launched a video game and wearable to help people living with hemophilia.
“These new digital innovations can be integrated into everyday routines to help empower people with hemophilia to learn about and track different aspects relevant to their disease so that they can have informed conversations with their health care providers,” said Dr. Kevin W. Williams, chief medical officer, Pfizer Rare Disease, in a statement.
Hemocraft is a modification of the Minecraft video game created in partnership with the Entrepreneurial Game Studio at Drexel University and representatives from the hemophilia community. The game aims to help individuals with hemophilia ages 8-16 learn the importance of integrating treatment into their routine in an educational and fun gaming environment.
Hemocraft players learn how to stick to their treatment plan, stay prepared and understand how treatment works. Throughout the game, players are challenged to monitor factor levels and self-infuse to help control bleeding, if needed.
“We are excited to see fun and educational tools that help people with a bleeding disorder, but equally as important, their friends and family to better understand the concept of factor levels in being able to stay active and stay in the game,” said Kate Nammacher, senior director of education, National Hemophilia Foundation, in a statement.
The HemMobile Striiv wearable offers an easy-to-use, comprehensive tool to track activity. The device, which can be worn on the wrist, includes features such as daily activity tracking and heart rate monitoring. The wristband integrates with Pfizer’s existing HemMobile app, which allows users to log bleeds and infusions, monitor their factor supply and set appointment reminders.
The data captured from the device generate personalized reports to provide a user’s health care team with insights that can help guide the discussion between a physician and their patient.
The HemMobile Striiv Wearable is available at no charge to anyone diagnosed with hemophilia in the U.S., regardless of what treatment they use.
“Ongoing innovation, coupled with our research, and support programs, continue to allow Pfizer to positively impact patients’ lives and pioneer a new era in hemophilia—today, and in the future,” said Williams.